RESEARCH
SCLCImmunotherapies
Longer OS in Asian than non-Asian patients given atezolizumab plus chemotherapy for extensive-stage SCLC
Read the article
Charles Rudin
Memorial Sloan Kettering Cancer Center, New York
Dr. Charles Rudin is Director of Memorial Sloan Kettering Cancer Center in New York, where he previously served a decade as Chief of the Thoracic Oncology Service. His research focuses on the molecular biology and treatment of lung cancer, with particular emphasis on small-cell lung cancer (SCLC). He has led multiple practice-changing trials in SCLC and NSCLC and is widely recognized for his work on tumor heterogeneity and targeted-therapy resistance mechanisms.
Connect
Charles Rudin
Featured in
Oct
04
2026
S. LiuM. ReckC. Rudin
Aug
09
2026
RESEARCH
Advanced NSCLCImmunotherapies
Radiation plus durvalumab without chemotherapy cleared its survival target in frail LA-NSCLC patients
Read the article
C. Rudin
Aug
03
2026
RESEARCH
SCLCImmunotherapies
Tarlatamab improved cough, breathlessness and chest pain against chemotherapy in DeLLphi-304
Read the article
C. RudinG. Mountzios
Dec
18
2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs
2025 Approvals & Highlights
1 h 49 min
S. PetersC. RudinM. Reck
